Advanced lung cancer patients suffer from deteriorated physical function, which negatively impacts physical and psychological health. As little is known about sleep and physical function in this population, this study aimed to examine the association between subjective and objective sleep parameters and physical function among them. 164 advanced lung cancer patients were included. Objective sleep was measured by actigraphy (measured on non-dominant wrist for 72 h), and subjective sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Performance-based physical function was measured by Timed Up and Go Test (TUGT), 6-Minute Walk Test (6MWT), Sit-to-Stand Test, and One-leg Standing Test. Univariable and multivariable regression analyses were employed to examine the association between sleep and physical function. Total sleep time (TST) was significantly associated with the 6MWT (β = 0.259; 95% CI 0.120, 0.398; P < 0.001), TUGT (β = − 0.012; 95% CI = − 0.017, − 0.008; P < 0.001) and Sit-to-Stand Test (β = 0.027; 95% CI = 0.018, 0.035; P < 0.001) after adjustment for multiple covariates. PSQI global score was only significantly associated with TUGT (β = 0.140; 95% CI = 0.000, 0.280; P = 0.050) after adjustment for multiple covariates. Shorter sleep duration significantly predicted poorer physical performance in advanced lung cancer patients, and more attention is required for those with less than 4.3 h of sleep on average.Trial registration: ClinicalTrials.gov, NCT03482323. Registered 29 March 2018, https://clinicaltrials.gov/ct2/show/NCT03482323; ClinicalTrials.gov, NCT04119778. Registered 8 October 2019, https://clinicaltrials.gov/ct2/show/NCT04119778.
Background: Patients with cancer may develop metastases to the orbit causing distressing symptoms.External beam radiation therapy (RT) is an effective palliative treatment for patients with orbital and ocular metastases. The aim of treatment is to preserve vision and to reduce pain. Delivery of 30 to 40 Gy in 2 Fr fractions is a practice in many oncology centres. The aim of this study is to evaluate the outcome of shortcourse palliative radiotherapy in the management of orbital and ocular metastases.Methods: A retrospective study to review all patients with orbital metastases treated in 2016 to 2018 were performed. The primary outcomes were a change in visual acuity and tumor response. Secondary outcomes included toxicities of radiotherapy, symptomatic response and survival.Results: Fifteen patients with 19 eyes were included. The most common presenting symptoms were decreased vision, periorbital swelling, and pain. The median follow-up period was 8 months. Visual acuity improved in 11 out of 13 (84.6%) of patients and remained stable in the remaining 2 patients. Partial and complete response (CR) of tumor was observed in 14 out of 15 (93.3%) of patients while one (6.6%) patient had stable disease. The overall response rate (ORR) was 100%. Two (13.3%) patients had grade 2 conjunctivitis. There were no grade 3-4 toxicities and no long-term toxicities observed. The median survival was 9.1 months from diagnosis of choroidal metastases.Conclusions: Short course palliative RT is effective and well tolerated in patients with orbital and ocular metastases. The current review showed that it effectively preserves vision and improves orbital symptoms with minimal radiation-induced toxicity. Short course radiotherapy will help to minimize the traveling time to the hospital and relieve the burden of a long treatment course in this palliative patient population.
Introduction: Currently, the three primary methods of detecting ALK rearrangement are fluorescent in situ hybridization, immunohistochemistry, and reverse transcriptase-polymerase chain reaction (RT-PCR). The former two methods use tissue as the laboratory materials, but some patients do not have sufficient tissue to perform the tests. The RT-PCR method can be conducted by both tissue and blood, but its detection of ALK rearrangement seems not sensitive enough. Digital PCR (dPCR) is a biotechnology refinement of conventional PCR methods that may be a more precise method than RT-PCR. Materials and Methods: An EML4-ALK variant 1 (v1) synthetic sequence, a variant 2 (v2) synthetic sequence, and a variant 3 (v3) non-small cell lung cancer (NSCLC) cell line (NCI-H2228) were used to evaluate the performance of our dPCR assay. To examine the performance PCR on clinical samples, we used both dPCR and RT-PCR assays to quantify the expression levels of EML4-ALK variants (v1, v2, and v3) in the circulating tumor RNAs derived from 414 plasma samples of 30 NSCLC patients during their ALK inhibitor treatment. Results: We have designed a multiplex dPCR assay for the detection of EML4-ALK in a v1 synthetic sequence (with 8,000 copies), a v2 synthetic sequence (with 10,000 copies), and a v3 cell line (with 100 copies). Our results showed high specificities and precisions (8,757 ± 592 copies, 11,070 ± 7,791 copies, and 93 ± 14 copies, respectively) for detecting all three variants simultaneously. On the other hand, our results observed good linearities (R2 = 0.9996, 0.9985, and 0.9991, respectively) in all three variants. To determine our dPCR assay's limit of detection for v1 and v2 synthetic sequences (each with four copies), our assay successfully measured the copy numbers of both v1 and v2 (4.1 ± 1.6 and 3.9 ± 1.8 copies, respectively). Comparing the sensitivities of our dPCR assay with RT-PCR assay, dPCR was able to detect down to 2 copies (for v1 and v2) and 20 pg of cDNA (for v3) while RT-PCR could only detect 200 copies (for v1 and v2) and 200 pg of cDNA (for v3). After confirming the promising performance of our dPCR assay, we tried to detect EML4-ALK variants by both dPCR and RT-PCR assays in the plasma samples of our recruited patients but mostly negative. Only one sample detected 39.2 copies of EML4-ALK v3 using dPCR assay. Conclusion: dPCR assay is a precise method with good performance at detecting EML4-ALK variants in synthetic sequences and cell line, which is more sensitive than RT-PCR. However, EML4-ALK variants could not be detected in the majority of our plasma samples. This may be due to insufficient circulating RNAs for detection. In addition, RNA may be degraded by RNase in plasma and that platelet may be a better alternative than plasma for the detection of RNAs in patient samples. Additional testing is warranted to detect EML4-ALK variants in the platelet samples of another NSCLC patient cohort. Citation Format: William C. Cho, Alvin H. Fong, King Y. Fung, Jeannie Y. Chik, Jacky Y. Li. Feasibility of digital PCR for the detection of ALK rearrangement in the plasma of non-small cell lung cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 468.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.